Cyprus Ranks Highest in European Union for Resistant Bacterial Bloodstream Infections
Cyprus ranks highest among European Union and European Economic Area countries for carbapenem resistant Klebsiella pneumoniae bloodstream infections according to European Centre for Disease Prevention and Control data. The European Centre for Disease Prevention and Control published the new data on November 18, 2026. This ranking highlights a significant public health challenge within the Cypriot healthcare system. The European Union has set 2030 targets for antimicrobial resistance that are currently not being met. These statistics underscore the urgency of strengthening infection control measures across the region.
Rising Infection Rates
The incidence rate in Cyprus for 2025 is estimated at 21.29 per 100,000 inhabitants. This figure represents a substantial public health concern when compared to the European average. The European average incidence rate for carbapenem resistant Klebsiella pneumoniae bloodstream infections is approximately 3.7 per 100,000 inhabitants. This disparity indicates that the infection burden in Cyprus is significantly higher than the continental mean. Health authorities must address these escalating rates to protect vulnerable populations.
The incidence rate in Cyprus has shown a continuous increase over recent years. In 2021, the incidence rate was 5.51 per 100,000 inhabitants. By 2024, the incidence rate reached 19.81 per 100,000 inhabitants. The subsequent rise to 21.29 per 100,000 inhabitants in 2025 demonstrates an accelerating trend. These figures illustrate a persistent and growing threat to patient safety within Cypriot hospitals and clinics. Monitoring these trends closely remains a priority for national health agencies.
Bacterial Resistance Threat
Carbapenem resistant Klebsiella pneumoniae can cause severe infections. These infections include pneumonia, urinary tract infections, and bloodstream infections. The severity of these infections is compounded by the bacteria's resistance to carbapenems. This resistance severely limits the available treatment options for infected patients. Healthcare providers face complex diagnostic and therapeutic challenges when treating these resistant strains. Effective infection prevention protocols are essential to mitigate these serious clinical outcomes.
These infections can progress to life-threatening sepsis. Sepsis is a severe complication that requires immediate and intensive medical intervention. The resistance of these bacteria to carbapenems directly impacts the efficacy of standard antibiotic regimens. Medical professionals must rely on alternative, often more toxic, antimicrobial agents. The European Centre for Disease Prevention and Control monitors these resistance patterns closely across member states. This surveillance helps inform national public health strategies and clinical guidelines.
European Health Targets
The European Union has established 2030 targets for antimicrobial resistance. These targets aim to reduce the incidence of drug-resistant infections across the bloc. Current data indicates that these established targets are not being met across the European Union. The European Centre for Disease Prevention and Control publishes comprehensive reports to track progress toward these goals. Member states are under increasing pressure to implement stricter infection control measures. Achieving these targets requires coordinated efforts from national governments and healthcare institutions.
This publication serves as a critical benchmark for national health ministries. The data provides a clear picture of the current state of antimicrobial resistance in the region. Addressing the high incidence rate in Cyprus requires immediate policy changes and increased investment in infection prevention infrastructure. Public awareness campaigns regarding antibiotic stewardship are also necessary components of a comprehensive national strategy. The future of patient care depends on controlling these resistant pathogens effectively.
Glossary
- European Union — The European Union has set 2030 targets for antimicrobial resistance. These targets aim to reduce the incidence of drug-resistant infections across the bloc. Current data indicates that these established targets are not being met across the European Union.
- European Economic Area — Cyprus ranks highest among European Union and European Economic Area countries for carbapenem resistant Klebsiella pneumoniae bloodstream infections according to European Centre for Disease Prevention and Control data. The European Centre for Disease Prevention and Control published the new data on November 18, 2026. This ranking highlights a significant public health challenge within the Cypriot healthcare system.
- member states — Member states are under increasing pressure to implement stricter infection control measures. Achieving these targets requires coordinated efforts from national governments and healthcare institutions. This publication serves as a critical benchmark for national
- European Centre for Disease Prevention and Control — The European Centre for Disease Prevention and Control is an agency of the European Union. Its mission is to strengthen Europe's defences against infectious diseases. It covers a wide spectrum of activities such as surveillance, epidemic intelligence, and scientific advice.
- antimicrobial resistance — Antimicrobial resistance is a naturally occurring process driven by the misuse and overuse of antimicrobials. It is a widespread serious threat that is happening right now in every region of the world. It has the potential to affect anyone, of any age, in any country.
This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact
Comments 0